Bladder Cancer Weekly

December 16, 2024

Videos

Peer-to-Peer Clinical Conversations

Real-World Treatments Following BCG Induction in Patients with NMIBC: A US Claims Analysis - Amanda Myers

Amanda Myers

Zachary Klaassen and Amanda Myers discuss a US claims analysis examining real-world treatment patterns following BCG induction in non-muscle invasive bladder cancer patients.

View

Expanded Access Program Provides Early Cretostimogene Therapy for Bladder Cancer - Sarah Psutka

Sarah Psutka

Sarah Psutka examines the expanded access program (EAP) for cretostimogene in BCG-unresponsive bladder cancer.

View

Beyond the Abstracts

Metastasis Development in Non-Muscle-Invasive Bladder Cancer - Beyond the Abstract

Gut Microbiota and Interstitial Cystitis: Exploring the Gut-Bladder Axis Through Mendelian Randomization, Biological Annotation and Bulk RNA Sequencing - Beyond the Abstract

Conference Coverage

SUO 2024: Long-Term Outcomes of Primary Chemoablation of Low-Grade UTUC with UGN-101, a Mitomycin Reverse Thermal Gel

SUO 2024: PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer

SUO 2024: Adjuvant Systemic Therapy in Urothelial Carcinoma: Where Are We At Today?

SUO 2024: E-cigarette Use and the Risk of Bladder Cancer

SUO 2024: Implementing Smoking Cessation in the Urologic Oncology Setting

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer.

Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer.

Perioperative Complications and Omission of Ureteral Stents During Robot-Assisted Radical Cystectomy with Intracorporeal Ileal Conduit.

Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab.

The need for a second transurethral resection in high-risk non-muscle-invasive bladder cancer based on the Vesicle Imaging-Reporting and Data System.

Urinary Diversion Versus Adverse In-Hospital Outcomes After Radical Cystectomy.

A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy.

Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function.

Safety and efficacy of the MP1000 surgical system in robot-assisted radical cystectomy: A prospective study.

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

Co-inhibition of PGF and VEGFA enhances the effectiveness of immunotherapy in bladder cancer.

Metastasis Development in Non-Muscle-Invasive Bladder Cancer - Beyond the Abstract

Tumor Location at Trans-Urethral Resection Is Predictive of Ipsilateral Pelvic Lymph-Nodal Metastases in Patients Undergoing Radical Cystectomy for Bladder Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login